Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of prostate cancer
3.2.1.2 Technological advancements
3.2.1.3 Rising awareness and screening programs
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Future market trends
3.10 Gap analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Therapy, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Hormonal therapy
5.3 Chemotherapy
5.4 Immunotherapy
5.5 Targeted therapy
5.6 Other therapies
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Androgen receptor inhibitors
6.3 GnRH receptor antagonist
6.4 PARP inhibitor
6.5 Immune checkpoint inhibitors
6.6 Other drug classes
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacy
8.3 Brick and mortar
8.4 E-commerce
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Astellas Pharma Inc.
10.2 AstraZeneca Plc
10.3 Bayer AG
10.4 Dendreon Pharmaceuticals LLC.
10.5 Exelixis, Inc
10.6 Ferring B.V.
10.7 GlaxoSmithKline Plc
10.8 Ipsen Pharma
10.9 Johnson & Johnson
10.10 Novartis AG
10.11 Pfizer Inc.
10.12 Sanofi S.A
10.13 Sumitomo Pharma America, Inc.
10.14 Takeda Pharmaceutical Company Limited
10.15 Tolmar Inc.
